ClinicalTrials.gg
TerminatedNCT03537157STOP-PERUpdated Sep 27, 2021

A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention

A Phase 2 interventional study of Rifaximin delayed release tablets and Placebo in Crohn Disease, sponsored by Alfasigma S.p.A.. Terminated at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-27.

Sponsored by Alfasigma S.p.A. · Phase 2, Interventional, and Prevention

Why this study was terminated
The decision to prematurely close the trial recruitment period was taken due to the difficulties in the recruitment of patients. This decision has not been triggered by any unexpected safety signals identified during the study conduction.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 205 studies in Crohn Disease with a site in Italy — 54 open to participants now, 78 under way, 29 of them phase 3. Crohn Disease · Italy.

Enrollment
135th of 163
43 · median 187
Started
2017
with 13 others
Phase 2
42 of 205
6 open now
Registered
94th of 205
by date

Among the 205 studies in Crohn Disease with a site in Italy, this one is the 135th largest by enrollment of the 163 interventional ones that give a count, is one of 14 that started in 2017, is one of 42 in phase 2, and was the 94th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

54 of the 205 studies in Crohn Disease with a site in Italy are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Crohn Disease with a site in Italy, or all of them as a file.
02

Study summary

Crohn's Disease (CD) is a chronic pathology characterized by exacerbations and remissions. Recurrent inflammation can cause bowel strictures, fistulae (often perianal) or abscesses. CD often requires intestinal resection. Surgery in CD is not curative, Therefore, endoscopic follow-up 6-12 months after surgery is recommended. Given the association between enteric bacteria and postoperative CD recurrence, antibacterial agents were shown to be effective in reducing the severity of endoscopic recurrence, but prolonged administration causes significant toxicity. The efficacy of "systemic antibiotics" and the experimental evidence of the central role of luminal flora as an essential factor in the development of post chirurgic CD recurrence provide the rationale for evaluating a locally acting antibiotic like Rifaximin.

Read the detailed description

Crohn's disease (CD) is a chronic, relapsing, remitting, systemic disease, which may result in transmural inflammation of the gastrointestinal tract. The precise aetiology is unknown: it is a lifelong disease arising from an interaction between genetic and environmental factors, but predominantly observed in developed countries of the world. CD can affect the entire digestive tract from the mouth to the anus, but the most commonly affected sites are the ileum and the ascending colon . The clinical course of CD is characterized by exacerbations and remissions. Therefore, recurrent inflammation can cause bowel strictures, fistulae (often perianal) or abscesses. Moreover, Crohn's disease (CD) often requires intestinal resection, despite treatment with immunosuppressive and biologic therapies.

Surgery in CD is not curative, and post-operative recurrence (POR) is a frequent event. Historically, up to 70% of patients who undergo CD-related resection develop postoperative endoscopic recurrence at or proximal to the surgical anastomosis within 1 year and approximately one-third of patients with CD, who have a first resection, require a second within 10 years.

Endoscopic lesions usually precede and correlate with future clinical recurrence (about 20-25% per year), and predict the development of Crohn's disease-related complications and the need for re-intervention.

Therefore, endoscopic follow-up 6-12 months after surgery is recommended. Given the association between enteric bacteria and postoperative CD recurrence, antibacterial agents directed against anaerobic bacteria (ornidazole and metronidazole) were shown to be effective in reducing the severity of endoscopic recurrence, but prolonged administration (more than 3 months) of these antibiotics causes significant toxicity, mainly neuropathy and gastrointestinal intolerance. The efficacy of "systemic antibiotics" and the experimental evidence of the central role of luminal flora as an essential factor in the development of post chirurgic CD recurrence provide the rationale for evaluating a locally acting antibiotic like Rifaximin in this condition.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Crohn Disease recurrence
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Crohn Disease with curative ileocolonic resection
  • Randomization within 45 days from ileocolonic resection or end or loop ileostomy within last year and closure occurred within 45 days from randomization
  • Fecal stream restoration at least 14 days prior to randomization
  • Presence of at least one risk factor for recurrence
  • Pregnancy protection on board during the study for childbearing female subjects

Exclusion criteria

Exclusion Criteria:

  • Presence of CD proximally or distally to the site of resection
  • Patients with strictureplasties at index surgery or ileorectal anastomosis
  • patients with active perianal CD
  • Patient treated with other treatments usually utilised for CD
  • Patients with active diseases with gastrointestinal involvement
  • intestinal obstruction or pseudo-obstruction
  • Patients presenting diarrhoea plus fever or bloody stools
  • Positivity to clostridium difficile toxin
  • Severe hepatic or renal impairment
  • Presence of severe cardiac insufficiency
  • to rifamycin antimicrobial agents
  • other conditions that would interfere or prevent the study completion
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Rifaximin delayed release tablets

    Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks

    Drug: Rifaximin delayed release tablets

  • Placebo comparator
    Placebo

    Two placebo tablets twice a day for 26 weeks

    Other: Placebo

Interventions

  • DrugRifaximin delayed release tablets

    Active intervention

  • OtherPlacebo

    Comparator placebo

06

What researchers measure

Primary outcomes

  1. Rutgeerts score

    Rate of patients presenting a rutgeerts score higher than or equal to i2 will be considered as endpoint. Endoscopic remission will be defined as a Rutgeerts score of i0 or i1 and recurrence defined as a Rutgeerts score of ≥i2 (i0, no lesions; i1, ≤5 aphthous lesions; i2, \>5 aphthous lesions or anastomotic ulcer \<1 cm; i3, diffuse aphthous ileitis with diffusely inflamed mucosa; i4, diffuse inflammation with large ulcers, nodules, and/or narrowing) at the anastomosis and neoterminal ileum. (Rutgeerts P, 1990)

    Time frame: 26 weeks

07

Study locations

1 site
  • Humanitas Clinical Research Center
    Rozzano, 20089, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jul 2020, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
May 25, 2018
StartActual
Nov 16, 2017
Primary completionActual
Jul 15, 2020
CompletionActual
Jul 29, 2020
Last update
Sep 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03537157
Lead sponsor
Alfasigma S.p.A.
Collaborators
Cromsource
Responsible party
Sponsor
First posted
May 25, 2018
Start date
Nov 16, 2017
Primary completion
Jul 15, 2020
Completion
Jul 29, 2020
Last update
Sep 27, 2021

Study contacts

Maria Grimaldi, MD
study director · Alfasigma S.p.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion